Scinai Immunotherapeutics Operating Cash Flow Growth & History (SCNI)

Scinai Immunotherapeutics's operating cash flow was −$6.0M for fiscal 2025.

View full Scinai Immunotherapeutics company overview

Scinai Immunotherapeutics annual operating cash flow history

Scinai Immunotherapeutics annual operating cash flow

Fiscal yearPeriod endedOperating cash flowChangeGrowth
20252025-12-31−$6.0M$304,000
20242024-12-31−$6.3M$3.0M
20232023-12-31−$9.4M−$2.1M
20222022-12-31−$7.3M$608,000
20212021-12-31−$7.9M$14.7M
20202020-12-31−$22.6M
20172017-12-31−$2.9M

Scinai Immunotherapeutics operating cash flow trends

Over the last five fiscal years, Scinai Immunotherapeutics's operating cash flow increased from −$22.6M to −$6.0M, a change of $16.5M. The latest reported quarter, Q2 2026, shows −$2.5M.

About the metric

What operating cash flow means

Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.

Calculation and source

SEC-reported operating cash flow

TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Scinai Immunotherapeutics source filings ↗

Community posts

It’s quiet here.

No posts about SCNI yet. Start the conversation.

Write the first post